Article info
PDFTherapeutic intervention
Neurological immune-related adverse events of ipilimumab
- Correspondence to Dr Ilja Bot, Department of Neurology, Antoni van Leeuwenhoek Hospital/Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands; i.bot{at}neuro.umcn.nl
Citation
Neurological immune-related adverse events of ipilimumab
Publication history
- First published March 13, 2013.
Online issue publication
April 14, 2016
Article Versions
- Previous version (14 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
Other content recommended for you
- Cardiotoxicity of immune checkpoint inhibitors
- Rare side effect of adjuvant ipilimumab after surgical resection of melanoma: Guillain-Barré syndrome
- Immune checkpoint inhibitor-induced hypophysitis: lessons learnt from a large cancer cohort
- Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events
- Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy
- Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma
- Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
- Evolving impact of long-term survival results on metastatic melanoma treatment
- Challenge of immune-mediated adverse reactions in the emergency department
- Central nervous system complications associated with immune checkpoint inhibitors